Calling Night-Time Episodes Of Low Blood Sugar 'Non-Severe' Is A 'Serious Misnomer' Say Researchers Who Uncovered Their High Cost

Published Nov 27, 2013
Copenhagen, Denmark - A new, international study published in Value in Health reveals the high economic and personal cost of seemingly non-severe episodes of hypoglycaemia (low blood sugar) suffered by people with diabetes at night while sleeping. According to the study, each non-severe nocturnal hypoglycaemic event (NSNHE) costs $127.00 per person, per episode, as a result of lost work productivity and health care use, and hence the study authors say the non-severe label is a ‘serious misnomer’. NSNHEs are so called because they do not require immediate medical attention or help from anyone else, however, they disrupt sleep and can affect functioning and wellbeing the next day. The study surveyed 2,108 people with type 1 and type 2 diabetes in nine countries in Europe and North America to evaluate the economic impact of these events in terms of lost work productivity and health care use (e.g., use of extra blood sugar tests and contacts with health care professionals). “Given these findings, we cannot ignore the serious consequences of so-called non-severe night-time episodes of hypoglycaemia on patients and the economy. We should consider treatments that can reduce night-time hypoglycaemia,” said lead investigator Meryl Brod, PhD, President, The Brod Group. The full study, “Understanding the Economic Burden of Nonsevere Nocturnal Hypoglycemic Events: Impact on Work Productivity, Disease Management, and Resource Utilization,” is published in Value in Health.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision-makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information:

Related Stories

Measuring What Matters: Broadening the Scope of Health Economics Evaluation to Incorporate Well-Being

Jul 9, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making.

Confronting the Backlash Against QALYs: Key Insights From Leading Health Economists

Jun 18, 2024

ISPOR announced the publication of a collection of papers that examine the long-standing debate surrounding the use of quality-adjusted life years (QALYs) and alternative measures in healthcare decision making.

ISPOR Good Practices Report Offers Guidance for Using Real-World Data From EHRs in Health Technology Assessments

Jun 17, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that proposes a framework for assessing the suitability of electronic health records data for use in health technology assessments. The report, “Assessing Real-World Data from Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force” was published in the June 2024 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now